GSK
Stock Details
GSK is GSK plc's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 43.78$. Average daily volumn in 3 months 5.7M. Market cap 110.65B
Stock symbol : GSK. Exchange : NYSE. Currency : USD Lastest price : 43.53$. Total volume : 4.11M. Market state PRE Click reload if you want to check the lastest price on market!!!
GSK plc (GSK)
Last Price
43.53$Change
-0.24Volume
4.11M
| Previous Close | 43.77 |
| Open | 43.22 |
| Day Range | 42.95-43.63 |
| Bid | 43.07 x 1.2k |
| Ask | 43.08 x 1.8k |
| Volume | 4.11M |
| Average Volume | 5.7M |
| Market Cap | 110.65B |
| Beta | 0.29 |
| 52 Week Range | 37.80-46.97 |
| Trailing P/E | 17.70 |
| Foward P/E | 12.44 |
| Dividend (Yield %) | 4.57% |
| Ex-Dividend Date | 2022-05-19 |
Financial Details
Organization
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory... , HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Market Cap:
110.65BRevenue:
34.11BTotal Assets:
79.1BTotal Cash:
4.27B
News about "GSK plc"
At $43.12, GSK plc (GSK) Is Worth Your Consideration
Source from : stocksregister - 22 hours ago
GSK plc (NYSE:GSK) at last check was buoying at $43.12 on Thursday, June 30, with a fall of -1.50% from its closing price on previous day. Taking a look at stock we notice that its last check on ...See details»
Wealthcare Advisory Partners LLC Has $207,000 Stock Position in GSK plc (NYSE:GSK)
Source from : Defense World - 9 hours ago
Wealthcare Advisory Partners LLC reduced its holdings in shares of GSK plc (NYSE:GSK – Get Rating) by 5.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange ...See details»
GSK plc (GSK): Does this stock hold the most enticing factor today?
Source from : investchronicle - 2 days ago
GSK plc (GSK) is priced at $43.35 after the most recent trading session. At the very opening of the session, the stock price was $43.59 and reached a high price of $43.75, prior to closing the session ...See details»
GSK plc (NYSE:GSK) Shares Sold by Gofen & Glossberg LLC IL
Source from : Defense World - 4 days ago
Gofen & Glossberg LLC IL decreased its holdings in GSK plc (NYSE:GSK – Get Rating) by 15.8% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 7,472 shares of the ...See details»
Investment Analysts’ Weekly Ratings Changes for GSK (GSK)
Source from : ETF Daily News - 2 days ago
The company has a quick ratio of 0.94, a current ratio of 1.19 and a debt-to-equity ratio of 147.36. GSK plc has a 52-week low of GBX 1,362.80 ($16.72) and a 52-week high of GBX 1,817 ($22.29). Get ...See details»
A Lesson to Learn: GSK plc (GSK)
Source from : newsheater - 8 days ago
GSK plc (NYSE:GSK) went up by 0.48% from its latest closing price compared to the recent 1-year high of $46.97. The company’s stock price has collected 1.77% of gains in the last five trading sessions ...See details»
Atticus Wealth Management LLC Purchases 500 Shares of GSK plc (NYSE:GSK)
Source from : ETF Daily News - 4 days ago
Atticus Wealth Management LLC raised its position in shares of GSK plc (NYSE:GSK – Get Rating) by 69.8% in the first quarter, according to the company in its most recent filing with the SEC. The ...See details»
GSK: Japan Accepts Regulatory Submission For Shingrix To Prevent Shingles In At Risk 18+
Source from : Nasdaq - 3 days ago
Brisith drug major GSK plc (GSK.L) announced Tuesday that Japan's Ministry of Health, Labour and Welfare or MHLW accepts Shingrix (Zoster Vaccine Recombinant, Adjuvanted) regulatory submission to ...See details»
Waiting for a GSK Mega Deal Hurts Like Toothache
Source from : Washington Post - 8 days ago
Reckitt would be a logical buyer for GSK’s consumer health spinoff Haleon. But the consumer goods giant should be in no rush.See details»
GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
Source from : Associated Press - 2 days ago
GSK plc today announced the first recipient of the Target the Future Think Tank Challenge £70,000 (equivalent to approximately $100,000) grant to the HealthTree Foundation, a non-profit organization ...See details»
GSK Shares Encouraging Data From Chronic Hepatitis B Candidate
Source from : YAHOO!Finance - 4 days ago
GSK plc (NYSE: GSK) announced promising interim results from the B-Clear phase 2b trial of bepirovirsen in people with chronic hepatitis B (CHB). The data showed that bepirovirsen reduced hepatitis B ...See details»
Sanofi-GSK Reports Positive Data From COVID-19 Beta-containing Vaccine Trial
Source from : Nasdaq - 7 days ago
Drug majors Sanofi (SNYNF, SNY) and GSK plc (GSK.L) announced Friday positive data from their vaccine trial which evaluated an adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. Sanofi-GSK ...See details»
GSK applies for shingles drug label expansion in Japan
Source from : Proactive Investors - 3 days ago
It wants doctors to be able to prescribe Shingrix to at-risk groups over the age of 18, including those with compromised immune systems ...See details»
Covid-19 Variant Shot From Sanofi, GSK Effective Against Omicron
Source from : Wall Street Journal - 7 days ago
The companies reported promising trial results for their Covid-19 vaccine that showed the shot—developed to target the Beta strain of the virus—was particularly effective against the Omicron variant.See details»